Revolution Healthcare Acquisition Corp. SAIL Warrant.
REVHW
REVHW was delisted on the 6th of December, 2022.
1 hedge funds and large institutions have $11 invested in Revolution Healthcare Acquisition Corp. SAIL Warrant. in 2022 Q4 according to their latest regulatory filings, with 0 funds opening new positions, 0 increasing their positions, 0 reducing their positions, and 37 closing their positions.
97% less funds holding
Funds holding: 39 → 1 (-38)
100% less capital invested
Capital invested by funds: $2.93M → $11 (-$2.93M)
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 37
Top Buyers
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RCM
Radcliffe Capital Management
Bala Cynwyd,
Pennsylvania
|
-$2.47M |
| 2 |
AGC
Angelo Gordon & Co
New York
|
-$196K |
| 3 |
TD Asset Management
Toronto,
Ontario, Canada
|
-$27K |
| 4 |
SRCM
Sage Rock Capital Management
New York
|
-$24K |
| 5 |
SC
Sculptor Capital
New York
|
-$21K |
REVHW Hedge Fund Activity: Q4 2022 in Review
1 of the 6,221 institutional investors tracked by Wall St. Rank reported a position in Revolution Healthcare Acquisition Corp. SAIL Warrant. (REVHW) for Q4 2022, worth a combined $11 — down 100% from $2.93M a quarter earlier.
Sellers outnumbered buyers: 37 funds closed out of REVHW and 0 opened new positions — a net loss of 37 holders — while 0 trimmed existing stakes and 0 added.
The largest seller was Radcliffe Capital Management, exiting entirely with an estimated $2.47M sold.
- 1 institutional investor held Revolution Healthcare Acquisition Corp. SAIL Warrant. (REVHW) as of Q4 2022, down from 39 in Q3 2022.
- Funds reported $11 of Revolution Healthcare Acquisition Corp. SAIL Warrant. stock for Q4 2022, down 100% quarter-over-quarter.
- 0 funds opened new Revolution Healthcare Acquisition Corp. SAIL Warrant. positions in Q4 2022 and 37 closed out, a net change of -37 holders.
- The largest Revolution Healthcare Acquisition Corp. SAIL Warrant. seller in Q4 2022 was Radcliffe Capital Management, an estimated $2.47M sold.
Based on aggregated 13F filings for Q4 2022.